Henry Schein, Inc. (NASDAQ:HSIC) Receives Consensus Rating of “Hold” from Analysts

Henry Schein, Inc. (NASDAQ:HSIC) has been assigned an average recommendation of “Hold” from the fifteen brokerages that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $87.6429.

A number of analysts recently issued reports on the stock. Weiss Ratings reissued a “hold (c+)” rating on shares of Henry Schein in a report on Monday, May 4th. Mizuho cut their price objective on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Citigroup began coverage on shares of Henry Schein in a research report on Wednesday, April 15th. They issued a “buy” rating and a $100.00 price objective for the company. Morgan Stanley reissued an “underweight” rating and set a $64.00 target price (up from $61.00) on shares of Henry Schein in a research note on Friday, April 24th. Finally, BMO Capital Markets began coverage on Henry Schein in a research report on Wednesday, July 8th. They set a “market perform” rating and a $85.00 target price on the stock.

Henry Schein Stock Up 1.3%

Shares of HSIC opened at $86.91 on Wednesday. Henry Schein has a 52 week low of $61.94 and a 52 week high of $89.29. The company has a quick ratio of 0.75, a current ratio of 1.36 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $9.90 billion, a price-to-earnings ratio of 26.26, a PEG ratio of 1.65 and a beta of 0.81. The stock’s 50-day moving average price is $78.51 and its 200-day moving average price is $77.48.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, May 5th. The company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.20 by $0.12. The firm had revenue of $3.37 billion for the quarter, compared to analyst estimates of $3.34 billion. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.Henry Schein’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same period last year, the company earned $1.15 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, sell-side analysts predict that Henry Schein will post 5.32 EPS for the current year.

Insider Transactions at Henry Schein

In other Henry Schein news, Director William K. Daniel purchased 10,000 shares of the stock in a transaction on Monday, May 11th. The shares were bought at an average price of $69.19 per share, for a total transaction of $691,900.00. Following the completion of the transaction, the director owned 20,000 shares of the company’s stock, valued at $1,383,800. This trade represents a 100.00% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 0.89% of the company’s stock.

Institutional Trading of Henry Schein

Institutional investors and hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC grew its stake in Henry Schein by 47.3% in the 1st quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock valued at $2,071,000 after acquiring an additional 9,756 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Henry Schein by 1.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock worth $1,155,000 after acquiring an additional 229 shares during the period. Acadian Asset Management LLC purchased a new position in Henry Schein during the first quarter valued at $676,000. Cetera Investment Advisers lifted its holdings in Henry Schein by 12.9% during the second quarter. Cetera Investment Advisers now owns 5,561 shares of the company’s stock valued at $406,000 after purchasing an additional 637 shares in the last quarter. Finally, First Trust Advisors LP grew its position in shares of Henry Schein by 0.8% in the second quarter. First Trust Advisors LP now owns 221,130 shares of the company’s stock valued at $16,154,000 after purchasing an additional 1,669 shares during the period. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.